AGY — Allergy Therapeutics Share News
0.000.00%
Last trade - 00:00- £500.27m
- £516.94m
- £55.04m
RCS - Allergy Therapeutics - EAACI Early Career Research Award
Brief: Allergy Therapeutics Posts H1 Net Income GBP -11.085 Million
Allergy Therapeutics - Interim Results for six months ended 31 Dec 2024
Brief: Allergy Therapeutics Enters Final Phase Of Treatment In Phase I/IIA VLP Peanut Protect Trial
Allergy Therapeutics - New Executive Long Term Incentive Awards
RCS - Allergy Therapeutics - Presentations at 2025 AAAAI / WAO Joint Congress
Brief: Allergy Therapeutics Announces Grass Mata Mpl Phase III Data Published In Allergy
Allergy Therapeutics - Grant of Options
Brief: Allergy Therapeutics Posts H1 Rev 34 Mln Stg
Allergy Therapeutics - Half Year Trading update
Allergy Therapeutics - PDMR Dealing and Total Voting Rights
Allergy Therapeutics - Director/PDMR Shareholding
Brief: Allergy Therapeutics Announces Positive Interim Analysis Data From Phase I/Iia Vlp Peanut Protect Trial
Allergy Therapeutics - First Patient Dosed in G308 Paediatric Trial
Brief: Allergy Therapeutics Submits MAA For Grass MATA MPL
Allergy Therapeutics - Notice of 2024 Annual General Meeting
Allergy Therapeutics - Audited Preliminary Results 2024
Brief: Allergy Therapeutics Commences Phase III Paediatric Trial
ZQ Capital Limited - Rule 19.6(c) Confirmation